ADC Therapeutics Q4 2025 Earnings Call Summary

ADC Therapeutics (ADCT) held its fourth-quarter earnings call for fiscal year 2025 on March 10, 2026. CEO Ameet Mallik and CFO Jose Carmona discussed operational performance and financial results. The company provided forward-looking statements with associated risks.

By Motley Fool Transcribing, The Motley Fool May 5, 2026 26 min read · Yahoo Finance · May 4, 2026, 23:05 UTC

ADC Therapeutics Q4 2025 Earnings Call Summary

Tickers: $ADCT

Topics: biotech financial results pharmaceuticals

Read the full article at Yahoo Finance

More World news

CytoDyn Secures $5 Million Private Placement for Leronlimab Development Seeking Alpha · November 12, 2026, 14:38 UTC
Cohen & Company Reports Q3 Earnings Miss on Declining Revenue and EPS Seeking Alpha · November 12, 2026, 14:39 UTC
Jensen Huang Resigns as Nvidia CEO Amid Investigation into Foreign Intelligence Allegations Motley Fool · November 12, 2026, 14:39 UTC
SuperCom Reports Q3 Fiscal 2026 Earnings Beat on Revenue and EPS Seeking Alpha · November 12, 2026, 14:35 UTC
Marvell Technology Appoints Three Independent Directors Prior to Proposed Lumentum Acquisition Seeking Alpha · November 12, 2026, 14:35 UTC
M-tron Industries Reports Q3 2026 GAAP EPS Miss Amid Low Revenue Seeking Alpha · November 12, 2026, 14:37 UTC
Nexxen International Reports Q3 Earnings Beat with Revenue Growth and Increased EBITDA Seeking Alpha · November 12, 2026, 14:30 UTC
Brookfield Corporation Announces Quarterly Dividend of $0.07 Per Share Seeking Alpha · November 12, 2026, 14:30 UTC
Upwork Expands Restructuring Plan to Reduce Workforce by 37% Seeking Alpha · November 12, 2026, 14:34 UTC
Deswell Industries Reports First-Half Revenue of $33.02 Million Amid Segment Shifts Seeking Alpha · November 12, 2026, 14:35 UTC